Business
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. CytoSorbents’ management team will be available for one-on-one meetings Monday, September 9, 2024. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to CytoSorbents’s website on the Events & Presentation page of the investors section for 90 days. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of June 30, 2024, more than 248,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult criticall...